LivaNova (NASDAQ:LIVN) Downgraded by StockNews.com to Hold

LivaNova (NASDAQ:LIVN) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

Several other equities analysts have also recently issued reports on LIVN. Mizuho reiterated a “buy” rating and set a $75.00 price target on shares of LivaNova in a research report on Wednesday, March 27th. Needham & Company LLC reiterated a “buy” rating and set a $72.00 price target on shares of LivaNova in a research report on Wednesday, March 20th. Barclays lifted their target price on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Finally, Robert W. Baird lifted their target price on LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, February 22nd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $64.40.

LivaNova Stock Performance

Shares of NASDAQ LIVN traded down $1.31 during mid-day trading on Wednesday, hitting $51.87. The company had a trading volume of 484,959 shares, compared to its average volume of 610,994. The firm’s 50 day simple moving average is $53.51 and its two-hundred day simple moving average is $50.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 162.10 and a beta of 0.89. LivaNova has a 12 month low of $42.75 and a 12 month high of $59.86.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.10. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The firm had revenue of $310.10 million for the quarter, compared to the consensus estimate of $287.65 million. During the same quarter in the previous year, the business earned $0.81 EPS. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. As a group, equities research analysts forecast that LivaNova will post 3.01 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC purchased a new position in shares of LivaNova during the second quarter valued at $46,000. Headlands Technologies LLC acquired a new stake in LivaNova during the third quarter valued at $72,000. Point72 Middle East FZE acquired a new stake in LivaNova during the fourth quarter valued at $72,000. Picton Mahoney Asset Management acquired a new stake in LivaNova during the third quarter valued at $91,000. Finally, PNC Financial Services Group Inc. boosted its position in LivaNova by 16.7% during the second quarter. PNC Financial Services Group Inc. now owns 2,853 shares of the company’s stock valued at $147,000 after purchasing an additional 408 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.